CenExel Clinical Research has kicked off the new year with acquisitions of clinical research sites located in Los Angeles and Denver.

The acquisitions were done to bolster the research capabilities of CenExel in the central nervous system (CNS) and movement disorder spaces.

The LA site, California Neuroscience Research, which will now take on the name CenExel CNR, mainly focuses on Alzheimer’s disease, depression, anxiety and migraine. The Denver site, Rocky Mountain Movement Disorders Center, addresses Parkinson’s disease, Huntington’s disease, essential tremor and other movement disorder trials and will change its name to CenExel Rocky Mountain Clinical Research.

CenExel’s network now spans 13 sites in the U.S. with a focus on neurology, pain, psychiatry, vaccines/immunology, sleep, clinical pharmacology, dermatology and ethnic-bridging studies, according to the company.